http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2005518403-A

Outgoing Links

Predicate Object
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K8-35
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C45-59
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C49-753
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61Q7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C49-713
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61Q19-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C49-603
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-02
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C49-753
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K8-35
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C49-713
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K8-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K8-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P5-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-122
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K8-90
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P19-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C45-59
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P17-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61Q19-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P17-02
filingDate 2003-01-09-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationDate 2005-06-23-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber JP-2005518403-A
titleOfInvention Compounds that block the androgen receptor
abstract Compounds used to block non-essential androgen receptors are described. In particular, cyclohexenone compounds containing alkyl groups can be used to treat conditions mediated by blocking of non-essential androgen receptors, such as pressure ulcers, male pattern folds, keloids, cutaneous folds, and osteoarthritis. The cyclohexenone compound can be administered orally, topically, or internally. Typically, the alkyl group is CH 3 and the cyclohexenone compound is 3- (5-methoxyheptyl) -2-cyclohexenone.
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2009507016-A
priorityDate 2002-01-09-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID25043
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID13717
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419506465
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID421842924
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5280489
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP15502
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP04985
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP07916
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID56841910
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID10236123
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID13594
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID447941096
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID444795
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID2006
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419516292
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419551405
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP54320
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP11547
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCQ99372
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID421846420
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID23505225
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5353436
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID426078961
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID103183906

Total number of triples: 60.